Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 ABT-767 study in BRCA-mutated advanced solid tumors and high-grade serous ovarian-related cancers
NL-OMON44086Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abt-767 in Nonhematologic neoplasms, ovarian cancer, fallopian tube cancer (PFTC) and 1 more (3 arms), sponsored by AbbVie Inc. Primary endpoints: Safety, Pharmacokinetics of ABT-767 and 2 more. Started Mar 2011; status: active, not recruiting.
02
Drugs
abt-767
03
Conditions
Nonhematologic neoplasmsovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON44086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44086.